The article explores a study published in Nature Medicine that examines the potential benefits and risks of glucagon-like peptide-1 receptor agonist drugs across 175 health outcomes in individuals with type 2 diabetes.Anderer, SamanthaJAMA: Journal of the American Medical Associ...
21, 2025 -- For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased risk for others, including gastrointestinal ...
Diabetes treatments vary significantly between Type 1 and Type 2 diabetes and include a range of medications and devices designed to manage blood sugar levels. While Type 1 diabetes primarily requires insulin therapy, Type 2 can be managed with lifestyle changes, oral medications, and in severe ca...
U.S. regulators approved Wegovy for lowering heart risks in March. Lilly's Zepbound has improved sleep apnea symptoms in trials, and analysts expect it to be approved for that indication by early next year. The drugs, from a class of medicines that also treat type ...
The rapidly evolving landscape of GLP-1 agonists [2:15]; The mechanism of GLP-1 agonists, their origin as diabetes treatments, and how they evolved into weight-loss drugs [6:45]; Overview of the new data and open questions related to the benefits and risks of GLP-1 agonists [10:30];...
Here are the health benefits of longan fruit.1. Improves MemoryLongan fruit is nootropic in nature. It means that the fruit extract enhances cognitive function and memory. In traditional Chinese medicine, longan fruit tonic is for anxiety-induced treatment....
(GLP-1RAs) and DPP-4i overcame the instability shortcoming of GLP-1 and became an important class of glycemic lowering drugs that are safe or beneficial to cardiovascular disease. GLP-1RAs reduce multiple cardiovascular risks such as hypertension, hyperglycemia, dyslipidemia, overweight, and insulin...
Weight management drugs now lead drug spending increases, study finds Alan Goforth | March 27, 2025 Claims data also show rapid adoption of GLP-1 for weight loss, with a steady increase in utilization since 2021 and peaking at 213.8% in 2023. News Supreme Court to hear case challengin...
Starting therapy with an SGLT2 inhibitor versus a glucagon-like peptide-1 (GLP-1) receptor agonist was associated with more lower limb amputations, nonvertebral fractures, and genital infections, but these risks need to be balanced against cardiovascular and renoprotective benefits, according to the ...
The research also points to important and perhaps underappreciated risks of these drugs. These risks primarily involved the digestive system and included nausea and vomiting, stomach pain, heartburn and gastroparesis, or stomach paralysis.Beyond the gut, people who took GLP-1 medications were al...